Clinical Trials Using FPV Vaccine CV301

Clinical trials are research studies that involve people. The clinical trials on this list are studying FPV Vaccine CV301. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • Nivolumab and Chemotherapy with or without CV301 Vaccine in Treating Patients with Resectable Hepatic-Limited Metastatic Colorectal Cancer

    This phase II trial studies how well nivolumab and chemotherapy, with or without the CV301 vaccine, works in treating patients with colorectal cancer that has spread only to the liver (hepatic-limited metastatic) and can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies such as nivolumab may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vaccines such as CV301 are made from gene-modified viruses and may help the body build an effective immune response to kill tumor cells. This study may help researchers determine if the combination of nivolumab and the CV301 vaccine works better than nivolumab only in treating patients with colorectal cancer. This study may also help researchers determine if nivolumab and the CV301 vaccine, when combined with standard chemotherapy and surgery, works better in treating patients with colorectal cancer when compared to chemotherapy and surgery only.
    Location: 4 locations

  • Durvalumab, MVA-BN-CV301, FPV Vaccine CV301, and Capecitabine with or without Bevacizumab in Treating Patients with Metastatic Colorectal or Pancreatic Cancer

    This phase I / II trial studies the side effects and best dose of durvalumab when given with modified vaccinia Ankara-Bavarian Nordic-CV301 (MVA-BN-CV301), FPV vaccine CV301, and capecitabine with or without bevacizumab and to see how well they work in treating patients with colorectal or pancreatic cancer that has spread to other places in the body. Monoclonal antibodies, such as durvalumab, may interfere with the ability of tumor cells to grow and spread. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. Drugs used in chemotherapy, such as capecitabine and bevacizumab, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Given durvalumab, MVA-BN-CV301, FPV vaccine CV301, and capecitabine with or without bevacizumab may work better in treating patients with colorectal or pancreatic cancer.
    Location: 3 locations